Dissolution Solutions Network

News, Stories and Commentary from the Pharma Lab

FDA Accepts Amgen’s Biosimilar Biologics License Application For ABP 501

Posted on | January 26, 2016 | Comments Off

“Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab).

“If approved, we believe ABP 501 could serve as an important additional approved therapeutic option for patients with …more000801_0357_0233_tsls


Comments are closed.

  • Topics

  • Recent Posts

  • Pages

  • Meta

  • Network Links

    • follow me on Twitter